Meeting
2021 Genitourinary Cancers Symposium
Impact of angiotensin inhibitors on pathologic complete response with neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer (MIBC).
Authors
Jonathan Thomas
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Jonathan Thomas , Gregory Russell Pond , Catherine Curran , Dory Freeman , Praful Ravi , Matthew Mossanen , Mark A. Preston , Graeme S. Steele , Charlene Mantia , Bradley Alexander McGregor , Rakesh K. Jain , Guru Sonpavde
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Therapeutics
Citation
J Clin Oncol 39, 2021 (suppl 6; abstr 432)
DOI
10.1200/JCO.2021.39.6_suppl.432
Abstract #
432
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
FDG PET-CT imaging in assessing interim response to neoadjuvant cisplatin-based chemotherapy (NAC) in muscle invasive bladder cancer (MIBC): A prospective study.
First Author: Srikala S. Sridhar
Poster
2022 ASCO Genitourinary Cancers Symposium
Impact of angiotensin-converting enzyme inhibitors (ACEi) on pathologic complete response with neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer (MIBC).
First Author: Jonathan Thomas
Poster
2019 ASCO Annual Meeting
Defects in DNA repair genes and long-term survival in cisplatin-based neoadjuvant chemotherapy for muscle invasive bladder cancer (MIBC).
First Author: Benjamin Miron
Poster
2013 ASCO Annual Meeting
Randomized phase III trial of neoadjuvant chemotherapy (NAC) with methotrexate, doxorubicin, vinblastine, and cisplatin (MVAC) followed by radical cystectomy (RC) compared with RC alone for muscle-invasive bladder cancer (MIBC): Japan Clinical Oncology Group study, JCOG0209.
First Author: Hiroshi Kitamura